Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Chantix may also help people control drinking

A popular smoking cessation drug dramatically reduced the amount a heavy drinker will consume, a new Yale School of Medicine study has found.

2 Mar 2009

Immune system found to be more versatile than previously thought

By studying how mice fight off infection by intestinal worms - a condition that affects more than 1 billion people worldwide - scientists have discovered that the immune system is more versatile than has long been thought.

26 Feb 2009

New cancer treatment stops aggressive sarcomas

After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.

25 Feb 2009

Ondansetron shown to be a viable treatment option for opioid addiction

Scientists at Stanford University School of Medicine have discovered that a commonly available non-addictive drug can prevent symptoms of withdrawal from opioids with little likelihood of serious side effects.

18 Feb 2009

Handheld device provides on-the-spot DNA analysis to test tolerance to prescription drugs

A handheld device to predict whether patients will respond adversely to medication is one step closer to the market, thanks to a new partnership.

18 Feb 2009

Vitamin B and folic acid - a new and safe treatment for migraine

A new Australian study has revealed that the occurrence and intensity of migraine may be lessened by taking vitamin B and folic acid.

9 Feb 2009

Idenix Pharmaceuticals and GSK sign agreement for novel NNRTI for treatment of HIV

Idenix Pharmaceuticals, Inc. and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899.

8 Feb 2009

Vitamin and mineral supplement use high among U.S. children and teens

A large number of U.S. children and teens age 2 to 17 appear to use vitamin and mineral supplements, although most may not need them, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

2 Feb 2009

Magnesium sulphate protects babies against cerebral palsy

Giving pregnant mothers magnesium sulphate when they are at risk of very preterm birth can help protect their babies from cerebral palsy, according to an international review of research involving the University of Adelaide, Australia.

21 Jan 2009

CSL Behring receives FDA approval of RiaSTAP

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

19 Jan 2009

Salmonella prompts recall of Kellogg's snacks

Food and Drug Administration (FDA) officials in the United States have confirmed the presence of salmonella in a popular snack made by food giant Kellogg.

19 Jan 2009

Calls for cash and fogging to curb spread of dengue fever

As the Dengue fever outbreak in northern Queensland continues to claim new victims on a daily basis, many are calling for more funding to control the spread of the disease with some suggesting the only answer will be a fogging campaign.

19 Jan 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

American pharmaceutical giant Eli Lilly and Company today agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration (FDA), the Department of Justice announced today.

19 Jan 2009

Phase III studies of EXPAREL (DepoBupivacaine) from Pacira complete enrollment

Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced today that enrollment has been completed in two pivotal Phase III SIMPLE trials to evaluate the safety and efficacy of a single intraoperative administration of EXPAREL(TM) (DepoBupivacaine) for prolonged postoperative analgesia.

6 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).

1 Jan 2009

Ingredient in cough medicine could treat prostate cancer

A study published today in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer.

22 Dec 2008

AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium)

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old.

21 Dec 2008

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

The U.S. Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication – keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

21 Dec 2008